Literature DB >> 33426488

Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.

Mizuki Izawa1, Takeo Kosaka1, Kohei Nakamura2, Junna Oba2, Tomoyuki Hishida3, Hiroshi Hongo1, Shuji Mikami4, Hiroshi Nishihara2, Mototsugu Oya1.   

Abstract

INTRODUCTION: Most metastatic prostate cancers acquire the capacity for androgen-independent growth and become resistant to androgen deprivation therapy. A patient-focused treatment strategy is needed for aggressive castration-resistant prostate cancer. CASE
PRESENTATION: We report the case of a 62-year-old man who presented with prostatic adenocarcinoma who was treated by radiation and combined androgen blockade. After completion of first-line therapy, he was diagnosed with multiple metastatic castration-resistant prostate cancer in the lung. Second-line therapy with abiraterone acetate resulted in partial remission of the lung metastases. Thoracic surgery was performed to remove the single lung metastasis remaining. Next-generation sequencing of the specimens demonstrated homozygous loss of BRCA2. We note in this case a heterogeneous response to abiraterone acetate may be related to the somatic BRCA2 deletions.
CONCLUSIONS: We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Entities:  

Keywords:  BRCA2; DNA damage repair genes; abiraterone acetate; next‐generation sequencing; prostate cancer

Year:  2020        PMID: 33426488      PMCID: PMC7784740          DOI: 10.1002/iju5.12224

Source DB:  PubMed          Journal:  IJU Case Rep        ISSN: 2577-171X


  14 in total

1.  Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.

Authors:  Eiko Saito; Megumi Hori; Tomohiro Matsuda; Daisuke Yoneoka; Yuri Ito; Kota Katanoda
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-13       Impact factor: 4.254

2.  Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy.

Authors:  Keitaro Watanabe; Takeo Kosaka; Eriko Aimono; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya
Journal:  Clin Genitourin Cancer       Date:  2019-06-13       Impact factor: 2.872

3.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Authors:  Wassim Abida; Joshua Armenia; Anuradha Gopalan; Ryan Brennan; Michael Walsh; David Barron; Daniel Danila; Dana Rathkopf; Michael Morris; Susan Slovin; Brigit McLaughlin; Kristen Curtis; David M Hyman; Jeremy C Durack; Stephen B Solomon; Maria E Arcila; Ahmet Zehir; Aijazuddin Syed; Jianjiong Gao; Debyani Chakravarty; Hebert Alberto Vargas; Mark E Robson; Vijai Joseph; Kenneth Offit; Mark T A Donoghue; Adam A Abeshouse; Ritika Kundra; Zachary J Heins; Alexander V Penson; Christopher Harris; Barry S Taylor; Marc Ladanyi; Diana Mandelker; Liying Zhang; Victor E Reuter; Philip W Kantoff; David B Solit; Michael F Berger; Charles L Sawyers; Nikolaus Schultz; Howard I Scher
Journal:  JCO Precis Oncol       Date:  2017-05-31

4.  Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Chao Liang; Hao Wang; Yan Chen; John L Silberstein; Danilo Piana; Zhao Lai; Yidong Chen; William B Isaacs; Jun Luo
Journal:  Eur Urol       Date:  2018-02-10       Impact factor: 20.096

Review 5.  Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.

Authors:  Naohiro Fujimoto
Journal:  J UOEH       Date:  2016-06-01

6.  Genomic testing for pancreatic cancer in clinical practice as real-world evidence.

Authors:  Hideyuki Hayashi; Shigeki Tanishima; Kyoko Fujii; Ryo Mori; Yasunobu Okamura; Emmy Yanagita; Ryosuke Matsuoka; Toraji Amano; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka-Akita; Hiroshi Nishihara
Journal:  Pancreatology       Date:  2018-07-25       Impact factor: 3.996

7.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 8.  A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.

Authors:  Grace A Martin; Adrienne H Chen; Kinjal Parikh
Journal:  Pharmacotherapy       Date:  2017-11       Impact factor: 4.705

9.  Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Authors:  Vivek L Patel; Evan L Busch; Tara M Friebel; Angel Cronin; Goska Leslie; Lesley McGuffog; Julian Adlard; Simona Agata; Bjarni A Agnarsson; Munaza Ahmed; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Adalgeir Arason; Norbert Arnold; Grazia Artioli; Brita Arver; Bernd Auber; Jacopo Azzollini; Judith Balmaña; Rosa B Barkardottir; Daniel R Barnes; Alicia Barroso; Daniel Barrowdale; Muriel Belotti; Javier Benitez; Birgitte Bertelsen; Marinus J Blok; Istvan Bodrogi; Valérie Bonadona; Bernardo Bonanni; Davide Bondavalli; Susanne E Boonen; Julika Borde; Ake Borg; Angela R Bradbury; Angela Brady; Carole Brewer; Joan Brunet; Bruno Buecher; Saundra S Buys; Santiago Cabezas-Camarero; Trinidad Caldés; Almuth Caliebe; Maria A Caligo; Mariarosaria Calvello; Ian G Campbell; Ileana Carnevali; Estela Carrasco; Tsun L Chan; Annie T W Chu; Wendy K Chung; Kathleen B M Claes; Gemo Study Collaborators; Embrace Collaborators; Jackie Cook; Laura Cortesi; Fergus J Couch; Mary B Daly; Giuseppe Damante; Esther Darder; Rosemarie Davidson; Miguel de la Hoya; Lara Della Puppa; Joe Dennis; Orland Díez; Yuan Chun Ding; Nina Ditsch; Susan M Domchek; Alan Donaldson; Bernd Dworniczak; Douglas F Easton; Diana M Eccles; Rosalind A Eeles; Hans Ehrencrona; Bent Ejlertsen; Christoph Engel; D Gareth Evans; Laurence Faivre; Ulrike Faust; Lídia Feliubadaló; Lenka Foretova; Florentia Fostira; George Fountzilas; Debra Frost; Vanesa García-Barberán; Pilar Garre; Marion Gauthier-Villars; Lajos Géczi; Andrea Gehrig; Anne-Marie Gerdes; Paul Gesta; Giuseppe Giannini; Gord Glendon; Andrew K Godwin; David E Goldgar; Mark H Greene; Angelica M Gutierrez-Barrera; Eric Hahnen; Ute Hamann; Jan Hauke; Natalie Herold; Frans B L Hogervorst; Ellen Honisch; John L Hopper; Peter J Hulick; KConFab Investigators; Hebon Investigators; Louise Izatt; Agnes Jager; Paul James; Ramunas Janavicius; Uffe Birk Jensen; Thomas Dyrso Jensen; Oskar Th Johannsson; Esther M John; Vijai Joseph; Eunyoung Kang; Karin Kast; Johanna I Kiiski; Sung-Won Kim; Zisun Kim; Kwang-Pil Ko; Irene Konstantopoulou; Gero Kramer; Lotte Krogh; Torben A Kruse; Ava Kwong; Mirjam Larsen; Christine Lasset; Charlotte Lautrup; Conxi Lazaro; Jihyoun Lee; Jong Won Lee; Min Hyuk Lee; Johannes Lemke; Fabienne Lesueur; Annelie Liljegren; Annika Lindblom; Patricia Llovet; Adria Lopez-Fernández; Irene Lopez-Perolio; Victor Lorca; Jennifer T Loud; Edmond S K Ma; Phuong L Mai; Siranoush Manoukian; Veronique Mari; Lynn Martin; Laura Matricardi; Noura Mebirouk; Veronica Medici; Hanne E J Meijers-Heijboer; Alfons Meindl; Arjen R Mensenkamp; Clare Miller; Denise Molina Gomes; Marco Montagna; Thea M Mooij; Lidia Moserle; Emmanuelle Mouret-Fourme; Anna Marie Mulligan; Katherine L Nathanson; Marie Navratilova; Heli Nevanlinna; Dieter Niederacher; Finn C Cilius Nielsen; Liene Nikitina-Zake; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Kai-Ren Ong; Ana Osorio; Claus-Eric Ott; Domenico Palli; Sue K Park; Michael T Parsons; Inge Sokilde Pedersen; Bernard Peissel; Ana Peixoto; Pedro Pérez-Segura; Paolo Peterlongo; Annabeth Høgh Petersen; Mary E Porteous; Miguel Angel Pujana; Paolo Radice; Juliane Ramser; Johanna Rantala; Muhammad U Rashid; Kerstin Rhiem; Piera Rizzolo; Mark E Robson; Matti A Rookus; Caroline M Rossing; Kathryn J Ruddy; Catarina Santos; Claire Saule; Rosa Scarpitta; Rita K Schmutzler; Hélène Schuster; Leigha Senter; Caroline M Seynaeve; Payal D Shah; Priyanka Sharma; Vivian Y Shin; Valentina Silvestri; Jacques Simard; Christian F Singer; Anne-Bine Skytte; Katie Snape; Angela R Solano; Penny Soucy; Melissa C Southey; Amanda B Spurdle; Linda Steele; Doris Steinemann; Dominique Stoppa-Lyonnet; Agostina Stradella; Lone Sunde; Christian Sutter; Yen Y Tan; Manuel R Teixeira; Soo Hwang Teo; Mads Thomassen; Maria Grazia Tibiletti; Marc Tischkowitz; Silvia Tognazzo; Amanda E Toland; Stefania Tommasi; Diana Torres; Angela Toss; Alison H Trainer; Nadine Tung; Christi J van Asperen; Frederieke H van der Baan; Lizet E van der Kolk; Rob B van der Luijt; Liselotte P van Hest; Liliana Varesco; Raymonda Varon-Mateeva; Alessandra Viel; Jeroen Vierstraete; Roberta Villa; Anna von Wachenfeldt; Philipp Wagner; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Greet Wieme; Siddhartha Yadav; Drakoulis Yannoukakos; Sook-Yee Yoon; Cristina Zanzottera; Kristin K Zorn; Anthony V D'Amico; Matthew L Freedman; Mark M Pomerantz; Georgia Chenevix-Trench; Antonis C Antoniou; Susan L Neuhausen; Laura Ottini; Henriette Roed Nielsen; Timothy R Rebbeck
Journal:  Cancer Res       Date:  2019-11-13       Impact factor: 13.312

10.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Authors:  Joaquin Mateo; Heather H Cheng; Himisha Beltran; David Dolling; Wen Xu; Colin C Pritchard; Helen Mossop; Pasquale Rescigno; Raquel Perez-Lopez; Verena Sailer; Michael Kolinsky; Ada Balasopoulou; Claudia Bertan; David M Nanus; Scott T Tagawa; Heather Thorne; Bruce Montgomery; Suzanne Carreira; Shahneen Sandhu; Mark A Rubin; Peter S Nelson; Johann S de Bono
Journal:  Eur Urol       Date:  2018-02-08       Impact factor: 20.096

View more
  2 in total

1.  Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.

Authors:  Tomohiro Iwasawa; Takeo Kosaka; Yota Yasumizu; Hiroshi Hongo; Yoshinori Yanai; Yuto Baba; Kazuhiro Matsumoto; Kohei Nakamura; Hiroshi Nishihara; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2022-10-21       Impact factor: 3.850

2.  Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.

Authors:  Ken Kamisawa; Takeo Kosaka; Kohei Nakamura; Yota Yasumizu; Hiroshi Hongo; Toshikazu Takeda; Kazuhiro Matsumoto; Hiroshi Nishihara; Mototsugu Oya
Journal:  Cancer Sci       Date:  2022-07-18       Impact factor: 6.518

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.